Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|15|30|3496-3501

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.30, 2009-10, pp. : 3496-3501

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter   Svenstrup Niels   Tinel Hanna   Haning Helmut   Bischoff Erwin  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite